2269:HKG
WuXi Biologics (Cayman) Inc
48,20 HKD
arrow_downward
-0,90%(-0,44) 1 d.
16. 10., 16:08:14 GMT+8 · HKD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre 2269…
Otvoriť
49,98 HKD
Vysoká
50,85 HKD
Nízka
45,82 HKD
Trh. kap.
198,43 mld.
Priem. obj.
30,42 mil.
Objem
55,18 mil.
Pomer cena/zárobky
34,48
Max. za 52 týž.
58,00 HKD
Min. za 52 týž.
28,48 HKD
Výnosy na akciu
1,40 HKD
Akcie v obehu
1,23 mld.
Počet zamestnancov
15 tis.
Otvoriť
49,98 HKD
Vysoká
50,85 HKD
Nízka
45,82 HKD
Trh. kap.
198,43 mld.
Priem. obj.
30,42 mil.
Objem
55,18 mil.
Pomer cena/zárobky
34,48
Max. za 52 týž.
58,00 HKD
Min. za 52 týž.
28,48 HKD
Výnosy na akciu
1,40 HKD
Akcie v obehu
1,23 mld.
Počet zamestnancov
15 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Billionaires.Africa
·
pred 7 minútami
South African financier Glen Steward on his road to Nasdaq
Bloomberg.com
·
pred 1 hodinou
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Yahoo Finance
·
pred 13 hodinami
Michael Burry Warns of a Stock Market ‘Supervolcano’
MarketWatch
·
pred 9 hodinami
These surprising stocks could be some of the biggest drivers of S&P 500 earnings growth
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Informácie o subjekte WuXi Biologics (Cayman) Inc
Generálny riaditeľZhisheng Chen
Zamestnanci14,7 tis.
Dátum založenia2010
Hlavné sídlo-
Odvetvie-